BC Innovations | Dec 4, 2018
Distillery Therapeutics


INDICATION: Non-small cell lung cancer (NSCLC) Cell culture and mouse studies suggest inhibiting AURKA, AURKB and AURKC could enhance the efficacy of T790M-mutant EGFR inhibitors against EGFR-mutant NSCLC. Screening of 94 compounds against cancer pathway...
BioCentury | Dec 9, 2017
Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
BC Innovations | Mar 31, 2016
Translation in Brief

Slow and steady

AstraZeneca plc (LSE:AZN; NYSE:AZN) and Bind Therapeutics Inc. (NASDAQ:BIND) have joined forces to stretch the therapeutic index of a kinase inhibitor that had stumbled in the clinic. The partners developed a nanoparticle formulation that slowed...
BC Week In Review | Dec 7, 2015
Clinical News

AZD2811: Phase I started

AstraZeneca began an open-label, U.S. Phase I trial to evaluate AZD2811 in about 77 patients. A dose-escalation part will determine the dose for the dose-expansion part, which will evaluate AZD2811 alone and with irinotecan. Dosing...
BC Week In Review | Jul 13, 2015
Clinical News

Bind Therapeutics, AstraZeneca preclinical data

In mouse xenograft models of small cell lung cancer (SCLC) and diffuse large B cell lymphoma (DLBCL), AZD2811 inhibited tumor growth and led to tumor regression. Data were presented at the American Association for Cancer...
Items per page:
1 - 5 of 5